Sir, HIV-2 or dual HIV-1/2 infection makes up between 4% and 24% of all HIV infections in West Africa, and dual infection $12% of all infections in Ghana. 1 HIV-2 infection progresses to AIDS more slowly than HIV-1; however, dual infection appears to progress at a rate similar to that of HIV-1.
2 Antiretroviral therapy (ART) has been widely available in Ghana since 2003, with good initial results. 3 Non-nucleoside reverse transcriptase inhibitor (NNRTI)-based ART is first-line therapy. In many centres HIV testing has not routinely been type-specific, so patients infected with HIV-2 have started ART including NNRTIs that are ineffective against HIV-2.
To analyse the impact of NNRTI-based ART in dual HIV-1/2 or HIV-2 seropositive individuals in terms of clinical outcomes, surrogate markers or resistance mutations, we conducted a retrospective study of patients attending a large HIV clinic in Ghana where type-specific HIV testing was not routine. The study was approved by the Committee on Human Research Publications and Ethics at KNUST, Kumasi. Patients were tested for HIV-2 seropositivity using the Immunocomb HIV-1&2 Biospot test (Orgenics, Yavne, Israel). Response to NNRTI-based ART, efavirenz/nevirapine with two nucleoside reverse transcriptase inhibitors (NRTIs), was compared in 57 dual HIV-1/2 seropositive, 16 HIV-2 seropositive and 197 HIV-1 seropositive patients who had completed at least 12 months of ART. Clinical and laboratory data were collected retrospectively at 6 monthly intervals. Changes in patient weight, total CD4 count and HIV viral load a minimum of 3 months after starting ART were compared. Mean values for (normally distributed) laboratory data were compared using t-tests and x 2 tests for categorical data. Baseline characteristics ( pre-ART) and responses to ART are shown in Table 1 . There were significantly more females in the HIV-2-infected groups. Increases in mean CD4 count at 6 and/or 12 months after starting ART were significantly lower in HIV-2 seropositive compared with HIV-1 and dual seropositive patients, despite starting from higher CD4 counts. Weight gain was also lower in this group. Samples were available to quantify HIV-2 and/or HIV-1 viral loads in a proportion of patients (HIV-2, 63%; dual seropositive, 56%; HIV-1, 22%) after a median of 14 months of ART. Whilst in the majority of dual seropositive and HIV-1 seropositive patients HIV-1+HIV-2 viral loads were suppressed on ART, only 19% of the HIV-2 seropositive patients achieved undetectable HIV-2 viral loads. There was little difference in the rates of AIDS-defining pathology between groups. Only one death was recorded, in a HIV-2 seropositive patient; however, a number of patients were lost to follow-up after the first year of ART. In samples from seven patients where it was possible to sequence the HIV-2 reverse transcriptase (RT) gene, the following polymorphisms associated with resistance were consistently identified: V75I, V118I, T215S and K219E (NRTI resistance); and Y181I, Y188L and G190A (NNRTI resistance). The only additional mutation identified consistently (different from the HIV-2 consensus sequence) was V111I.
The most interesting finding of this study was the relatively good response of the dual seropositive group to NNRTI-based therapy, in terms of immunological and viral load markers. The response to NNRTI-based ART was suboptimal in the HIV-2 seropositive group. Given the lack of activity of NNRTIs against HIV-2, these findings are not unexpected in patients who were effectively receiving dual NRTI therapy. One explanation may be that the pathogenic effect of HIV-2 viruses was lower in the dual seropositive patients than in the HIV-2 seropositive patients. Hence in dual seropositive individuals, where mainly HIV-1 was driving disease progression, NNRTI-based ART could have been sufficient to promote immunological recovery. Another explanation may be that dual seropositive patients were more likely to have better immunological outcomes as they started ART at less advanced WHO stages. Given the limited clinical and mortality data available, the clinical significance of these differences in response is uncertain.
The only other study to have compared response to ART ( protease inhibitor-based) between cohorts with HIV-1 and HIV-2 infection found greater increases in CD4 count in the HIV-2 group compared with the HIV-1 group after 12 months of ART. 4 One concern in HIV-2-infected patients taking non-suppressive ART is the development of resistance. We found mutations associated with resistance to NRTIs in all HIV-2 seropositive patients with amplifiable samples. The significance of the V111I mutation in the absence of other major mutations is not known, although it has been described elsewhere. 5 The effect of such mutations on the activity of other NRTIs in second-line regimens is not clear; however, alternative NRTIs may provide useful activity in second-line ( protease inhibitor-based) regimens onto which these patients are now being switched. 6 In conclusion, although this study is limited by the crosssectional nature of viral load results and incomplete clinical and mortality data, it appears that many dual HIV-1/2 seropositive patients may make adequate responses to NNRTI-based ART, whilst HIV-2 seropositive patients do not. Type-specific HIV testing to establish HIV-2 seropositivity is necessary in all newly diagnosed patients to optimize the benefits of first-line ART in Ghana.
